Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥18 years of age, ≥19 years in Korea, or ≥20 years for subjects in Japan and Taiwan~* Histologically confirmed diagnosis of CD20 positive iNHL with histological subtype limited to:~  1. FL Gr 1, Gr 2, or Gr 3a~ 2. MZL (splenic, nodal, or extra-nodal)~* Subjects with relapsed or refractory disease who received ≥1 prior lines of therapy~* Subjects must have at least one bi-dimensionally measurable lesion \>1.5 cm~* Adequate hematologic parameters at screening unless abnormal values are due to disease~* Adequate renal and hepatic function~* Adequate cardiac function based on ECG and LVEF assessments~Exclusion Criteria:~* Histologically confirmed diagnosis of FL Gr 3b or transformed disease~* Prior therapy with PI3K inhibitors~* Ongoing or history of drug-induced pneumonitis~* Known lymphomatous involvement of the central nervous system~* Tested positive for or active viral infection with hepatitis B or C virus~* Tested positive or active infection with human immunodeficiency virus~* Tested positive, or active infection with human T-cell leukemia virus type 1~* Any uncontrolled clinically significant illness~* History of clinically significant cardiovascular abnormalities such as congestive heart failure~* History of clinically significant gastrointestinal (GI) conditions~* Females who are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab plus Zandelisib (Type: EXPERIMENTAL): Rituximab plus Zandelisib for 6 cycles followed by Zandelisib for 20 cycles
- Rituximab plus chemotherapy (Type: EXPERIMENTAL): Rituximab and Bendamustine or Rituximab with (CHOP) for 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).